Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel

Title
Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel
Authors
Keywords
COVID-19, Drugs, hERG channel, QT interval, Long QT syndrome (LQTS)
Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 893, Issue -, Pages 173813
Publisher
Elsevier BV
Online
2020-12-18
DOI
10.1016/j.ejphar.2020.173813

Ask authors/readers for more resources

Reprint

Contact the author

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started